other material
confidence high
sentiment positive
materiality 0.85
Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones
Dianthus Therapeutics, Inc. /DE/
- Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).
- Additional up to $962M in development, regulatory, and sales-based milestones across five indications.
- Tiered royalties from mid-single digits to low double-digit on ex-Greater China net sales.
- Preliminary cash $555M as of Sep 30, 2025; pro forma $525M after $30M payment to Leads.